Diabetes drug tested as Pre-Surgery treatment for early lung cancer
NCT ID NCT07235280
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a diabetes drug called dapagliflozin is safe to give before surgery in people with early-stage lung adenocarcinoma. About 48 participants will take the drug for a short time before their planned surgery. The goal is to see if the drug can help make surgery more effective by targeting a protein found in high levels in these tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection